

FORM PTO-1390 (REV. 12-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER NEX86/PCT-US	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. 10/031193 <small>U.S. APPLICATION NO. IF KNOWN (see 37 CFR 1.5)</small>	
INTERNATIONAL APPLICATION NO. PCT/US00/02167		INTERNATIONAL FILING DATE 28 JANUARY 2000		PRIORITY DATE CLAIMED 29 JULY 1999	
TITLE OF INVENTION TENASCIN-C NUCLEIC ACID LIGANDS					
APPLICANT(S) FOR DO/EO/US HICKE, Brian; WARREN, Stephen; PARMA, David; GOLD, Larry					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
<b>Items 11 to 20 below concern document(s) or information included:</b>					
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A <b>FIRST</b> preliminary amendment. 14. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: Application Data Sheet; Abstract; Statement under 37 CFR 1.821(f); Postcard Receipt					

531 Rec'd PCTA 15 JAN 2002

U.S. APPLICATION NO. <u>107031193</u> INTERNATIONAL APPLICATION NO. <u>PCT/US00/02167</u>				ATTORNEY'S DOCKET NUMBER <u>NEX86/PCT-US</u>			
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... <b>\$1040.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>          <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: right;">\$ 710.00</td> <td style="width: 50%;"></td> </tr> </table>		\$ 710.00	
\$ 710.00							
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$			
Total claims	43 - 20 =	23	x <b>\$18.00</b>	\$ 414.00			
Independent claims	7 - 3 =	4	x <b>\$84.00</b>	\$ 336.00			
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$280.00</b>	\$			
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 1,460.00			
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$			
<b>SUBTOTAL =</b>				\$ 1,460.00			
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$			
<b>TOTAL NATIONAL FEE =</b>				\$ 1,460.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$			
<b>TOTAL FEES ENCLOSED =</b>				\$ 1,460.00			
				Amount to be refunded:	\$		
				charged:	\$		
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.  b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>22-0277</u> in the amount of \$ <u>1460.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>22-0277</u> . A duplicate copy of this sheet is enclosed.  d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card          information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.							
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR          1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>							
SEND ALL CORRESPONDENCE TO:  ROSEMARY KELLOGG Customer No. 25,871 SWANSON & BRATSCHUN, L.L.C. 1745 Shea Center Drive, Suite 330 Highlands Ranch, Colorado 80129 UNITED STATES OF AMERICA							
January 15, 2002			<u>Rosemary Kellogg</u> SIGNATURE ROSEMARY KELLOGG NAME 39,726 REGISTRATION NUMBER				

8 pts

WO 01/09390

107031193

PCT/US00/02167

10 RECEIVED 15 JAN 2002

## TENASCIN-C NUCLEIC ACID LIGANDS

### FIELD OF THE INVENTION

5 Described herein are high affinity nucleic acid ligands to tenascin-C. Also described herein are methods for identifying and preparing high affinity nucleic acid ligands to tenascin-C. The method used herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by Exponential enrichment. Further disclosed are high affinity nucleic acid ligands to tenascin-C. Further disclosed are  
10 RNA ligands to tenascin-C. Also included are oligonucleotides containing nucleotide derivatives chemically modified at the 2'-positions of the purines and pyrimidines. Additionally disclosed are RNA ligands to tenascin-C containing 2'-F and 2'OMe modifications. The oligonucleotides of the present invention are useful as diagnostic and/or therapeutic agents.

### BACKGROUND OF THE INVENTION

Tenascin-C is a 1.1-1.5 million Da, hexameric glycoprotein that is located primarily in the extracellular matrix. Tenascin-C is expressed during embryogenesis, wound healing, and neoplasia, suggesting a role for this protein in tissue remodeling (Erickson and Bourdon  
20 (1989) *Ann Rev Cell Biol* 5:71-92). Neoplastic processes also involve tissue remodeling, and tenascin-C is over-expressed in many tumor types including carcinomas of the lung, breast, prostate, and colon, astrocytomas, glioblastomas, melanomas, and sarcomas (Soini *et al.* (1993) *Am J Clin Pathol* 100(2):145-50; Koukoulis *et al.* (1991) *Hum Pathol* 22(7):636-43; Borsi *et al.* (1992) *Int J Cancer* 52(5):688-92; Koukoulis *et al.* (1993) *J Submicrosc Cytol*  
25 *Pathol* 25(2):285-95; Ibrahim *et al.* (1993) *Hum Pathol* 24(9):982-9; Riedl *et al.* (1998) *Dis Colon Rectum* 41(1):86-92; Tuominen and Kallioinen (1994) *J Cutan Pathol* 21(5):424-9; Natali *et al.* (1990) *Int J Cancer* 46(4):586-90; Zagzag *et al.* (1995) *Cancer Res* 55(4):907-14; Hasegawa *et al.* (1997) *Acta Neuropathol (Berl)* 93(5):431-7; Saxon *et al.* (1997) *Pediatr Pathol Lab Med* 17(2):259-66; Hasegawa *et al.* (1995) *Hum Pathol* 26(8):838-45). In  
30 addition, tenascin-C is overexpressed in hyperproliferative skin diseases, e.g. psoriasis (Schalkwijk *et al.* (1991) *Br J Dermatol* 124(1):13-20), and in atherosclerotic lesions (Fukumoto *et al.* (1998) *J Atheroscler Thromb* 5(1):29-35; Wallner *et al.* (1999) *Circulation* 99(10):1284-9). Radiolabeled antibodies that bind tenascin-C are used for imaging and therapy of tumors in clinical settings (Paganelli *et al.* (1999) *Eur J Nucl Med* 26(4):348-57;  
35 Paganelli *et al.* (1994) *Eur J Nucl Med* 21(4):314-21; Bigner *et al.* (1998) *J Clin Oncol*

16(6):2202-12; Merlo *et al.* (1997) *Int J Cancer* 71(5):810-6).

Aptamers against tenascin-C have potential utility for cancer diagnosis and therapy, as well as for diagnosis and therapy of atherosclerosis and therapy of psoriasis. Relative to antibodies, aptamers are small (7-20 kDa), clear very rapidly from blood, and are chemically synthesized. Rapid blood clearance is important for *in vivo* diagnostic imaging, where blood levels are a primary determinant of background that obscures an image. Rapid blood clearance may also be important in therapy, where blood levels may contribute to toxicity. SELEX technology allows rapid aptamer isolation, and chemical synthesis enables facile and site-specific conjugation of aptamers to a variety of inert and bioactive molecules. An aptamer to tenascin-C would therefore be useful for tumor therapy or *in vivo* or *ex vivo* diagnostic imaging and/or for delivering a variety of therapeutic agents complexed with the tenascin-C nucleic acid ligand for treatment of disease conditions in which tenascin-C is expressed.

The dogma for many years was that nucleic acids had primarily an informational role. Through a method known as Systematic Evolution of Ligands by EXponential enrichment, termed the SELEX process, it has become clear that nucleic acids have three dimensional structural diversity not unlike proteins. The SELEX process is a method for the *in vitro* evolution of nucleic acid molecules with highly specific binding to target molecules and is described in United States Patent Application Serial No. 07/536,428, filed June 11, 1990, entitled "Systematic Evolution of Ligands by EXponential Enrichment," now abandoned, United States Patent No. 5,475,096 entitled "Nucleic Acid Ligands," United States Patent No. 5,270,163 (see also WO 91/19813) entitled "Methods for Identifying Nucleic Acid Ligands," each of which is specifically incorporated by reference herein in its entirety. Each of these applications, collectively referred to herein as the SELEX Patent Applications, describes a fundamentally novel method for making a nucleic acid ligand to any desired target molecule. The SELEX process provides a class of products which are referred to as nucleic acid ligands or aptamers, each having a unique sequence, and which have the property of binding specifically to a desired target compound or molecule. Each SELEX-identified nucleic acid ligand is a specific ligand of a given target compound or molecule. The SELEX process is based on the unique insight that nucleic acids have sufficient capacity for forming a variety of two- and three-dimensional structures and sufficient chemical versatility available within their monomers to act as ligands (form specific binding pairs) with virtually any chemical compound, whether monomeric or polymeric. Molecules of any size or composition can

serve as targets in the SELEX method. The SELEX method applied to the application of high affinity binding involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection scheme, to achieve virtually any desired criterion of binding affinity and selectivity.

- 5 Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound specifically to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes
- 10 to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield highly specific high affinity nucleic acid ligands to the target molecule.

It has been recognized by the present inventors that the SELEX method demonstrates that nucleic acids as chemical compounds can form a wide array of shapes, sizes and

15 configurations, and are capable of a far broader repertoire of binding and other functions than those displayed by nucleic acids in biological systems.

The basic SELEX method has been modified to achieve a number of specific objectives. For example, United States Patent Application Serial No. 07/960,093, filed October 14, 1992, now abandoned, and United States Patent No. 5,707,796, both entitled

20 "Method for Selecting Nucleic Acids on the Basis of Structure," describe the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA. United States Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands," now abandoned, United States Patent No. 5,763,177, entitled "Systematic

25 Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX" and United States Patent Application Serial No. 09/093,293, filed June 8, 1998, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX," describe a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding

30 and/or photocrosslinking to and/or photoinactivating a target molecule. United States Patent No. 5,580,737, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, which can be non-peptidic,

termed Counter-SELEX. United States Patent No. 5,567,588, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule.

5           The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved *in vivo* stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX process-identified nucleic acid ligands containing modified nucleotides  
10           are described in United States Patent No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. United States Patent No. 5,580,737, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH<sub>2</sub>), 2'-fluoro (2'-F), and/or 2'-O-methyl  
15           (2'-OMe). United States Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Intramolecular Nucleophilic Displacement," now abandoned, describes oligonucleotides containing various 2'-modified pyrimidines.

          The SELEX method encompasses combining selected oligonucleotides with other  
20           selected oligonucleotides and non-oligonucleotide functional units as described in United States Patent No. 5,637,459, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Chimeric SELEX," and United States Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and  
25           other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules.

          The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic compounds or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in United States Patent Application Serial No.  
30           08/434,465, filed May 4, 1995, entitled "Nucleic Acid Ligand Complexes". Each of the above described patents and applications which describe modifications of the basic SELEX procedure are specifically incorporated by reference herein in their entirety.

## **SUMMARY OF THE INVENTION**

The present invention describes a method for isolating nucleic acid ligands that bind to tenascin-C with high specificity. Further described herein are nucleic acid ligands to tenascin-C. Also described herein are high affinity RNA ligands to tenascin-C. Further described are 2'fluoro-modified pyrimidine and 2'OMe-modified purine RNA ligands to tenascin-C. The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by Exponential enrichment. Included herein are the ligands that are shown in Tables 3 and 4 and Figure 10.

Further included in this invention is a method for detecting the presence of a disease that is expressing tenascin-C in a biological tissue that may contain the disease. Still further included in this invention is a method for detecting the presence of a tumor that is expressing tenascin-C in a biological tissue that may contain the tumor. Further included in this invention is a complex for use in *in vivo* or *ex vivo* diagnostics. Still further included in this invention is a method for delivering therapeutic agents for the treatment or prophylaxis of diseased tissues that express tenascin-C. Still further included in this invention is a complex for use in delivering therapeutic agents for treatment or prophylaxis of diseased tissues that express tenascin-C.

## **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 shows binding of Cell SELEX RNA pools to U251 cells.

Figure 2 shows proposed secondary structure of aptamers TTA1 and TTA1.NB. Included in the figure is the conjugation of the aptamers with Tc-99m chelator. All A's are 2'OMe modified. All G's, except as indicated, are 2'OMe modified. All C's and U's are 2'F modified.

Figure 3 shows images of U251 tumor xenografts in mice, obtained using Tc-99m-labeled TTA1 and TTA1.NB, three hours post-injection.

Figure 4 shows fluorescence microscopy of a U251 glioblastoma tumor section, taken three hours after i.v. injection of Rhodamine-Red-X-labeled TTA1.

Figure 5 shows the way in which the Tc-99m and linker is bound through the 5'G of TTA1.

Figure 6 describes TTA1/GS7641 uptake at 3 hours into various human tumor xenografts in mouse, compared to uptake of the non-binding control aptamer. ID/g = injected dose/gram.

Figure 7 displays the biodistribution of In-111 labeled TTA1/GS7641 using either DOTA or DTPA as the radiometal chelator, 3 hours after injection. ID/g = injected dose/gram.

Figure 8 shows the conjugation of the aptamer to DTPA. The <sup>111</sup>In is shown as  
5 chelated by DTPA.

Figure 9 shows the conjugation of the aptamer to DOTA. The <sup>111</sup>In is shown as chelated by DOTA.

Figure 10 shows the proposed secondary structure of aptamer TTA1. Included in the figure is the conjugation of the aptamer with Tc-99m chelator. The aptamer is shown in its  
10 Tc-99m labeled form. All A's are 2'OMe modified. All G's, except as indicated, are 2'OMe modified. All C's and U's are 2'F modified.

#### **DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS**

The central method utilized herein for identifying nucleic acid ligands to tenascin-C is  
15 called the SELEX process, an acronym for Systematic Evolution of Ligands by Exponential enrichment and involves (a) contacting the candidate mixture of nucleic acids with tenascin-C (b) partitioning between members of said candidate mixture on the basis of affinity to tenascin-C, and c) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to tenascin-C.

20 The invention includes RNA ligands to tenascin-C. This invention further includes the specific RNA ligands to tenascin-C shown in **Tables 3 and 4** and **Figure 10**. More specifically, this invention includes nucleic acid sequences that are substantially homologous to and that have substantially the same ability to bind tenascin-C as the specific nucleic acid ligands shown in **Tables 3 and 4** and **Figure 10**. By substantially homologous it is meant a  
25 degree of primary sequence homology in excess of 70%, most preferably in excess of 80%, and even more preferably in excess of 90%, 95%, or 99%. The percentage of homology as described herein is calculated as the percentage of nucleotides found in the smaller of the two sequences which align with identical nucleotide residues in the sequence being compared when 1 gap in a length of 10 nucleotides may be introduced to assist in that alignment.

30 Substantially the same ability to bind tenascin-C means that the affinity is within one or two orders of magnitude of the affinity of the ligands described herein. It is well within the skill of those of ordinary skill in the art to determine whether a given sequence – substantially homologous to those specifically described herein – has the same ability to bind tenascin-C.



A review of the sequence homologies of the nucleic acid ligands of tenascin-C shown in **Tables 3 and 4** and **Figure 10** shows that sequences with little or no primary homology may have substantially the same ability to bind tenascin-C. For these reasons, this invention also includes nucleic acid ligands that have substantially the same postulated structure or structural motifs and ability to bind tenascin-C as the nucleic acid ligands shown in **Tables 3** and **4** and **Figure 10**. Substantially the same structure or structural motifs can be postulated by sequence alignment using the Zukerfold program (see Zuker (1989) *Science* 244:48-52). As would be known in the art, other computer programs can be used for predicting secondary structure and structural motifs. Substantially the same structure or structural motif of nucleic acid ligands in solution or as a bound structure can also be postulated using NMR or other techniques as would be known in the art.

Further included in this invention is a method for detecting the presence of a disease that is expressing tenascin-C in a biological tissue which may contain the disease by the method of (a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, the nucleic acid ligand being a ligand of tenascin-C, by the method comprising (i) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; (ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

(iii) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C is identified; (b) attaching a marker that can be used in *in vivo* or *ex vivo* diagnostics to the nucleic acid ligand identified in step (iii) to form a marker-nucleic acid ligand complex; (c) exposing a tissue which may contain the disease to the marker-nucleic acid ligand complex; and (d) detecting the presence of the marker-nucleic acid ligand in the tissue, whereby a disease expressing tenascin-C is identified.

It is a further object of the present invention to provide a complex for use in *in vivo* or *ex vivo* diagnostics comprising one or more tenascin-C nucleic acid ligands and one or more markers. Still further included in this invention is a method for delivering therapeutic agents for the treatment or prophylaxis of disease conditions in which tenascin-C is expressed. Still further included in this invention is a complex for use in delivering therapeutic agents for treatment or prophylaxis of disease conditions in which tenascin-C is expressed.

### Definitions

Various terms are used herein to refer to aspects of the present invention. To aid in the clarification of the description of the components of this invention, the following definitions are provided:

5 As used herein, "nucleic acid ligand" is a non-naturally occurring nucleic acid having a desirable action on a target. Nucleic acid ligands are often referred to as "aptamers." The target of the present invention is tenascin-C, hence the term tenascin-C nucleic acid ligand. A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional  
10 activity of the target, covalently attaching to the target as in a suicide inhibitor, facilitating the reaction between the target and another molecule. In the preferred embodiment, the action is specific binding affinity for a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix  
15 binding, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. Nucleic acid ligands are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a tenascin-C, by the method comprising: a) contacting the candidate mixture with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be  
20 partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids (see U.S. Patent Application No. 08/434,425, filed May 3, 1995, now United States Patent No. 5,789,157, which is hereby incorporated herein by reference).

25 As used herein, "candidate mixture" is a mixture of nucleic acids of differing sequence from which to select a desired ligand. The source of a candidate mixture can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences  
30 surrounding a randomized region to facilitate the amplification process.

As used herein, "nucleic acid" means either DNA, RNA, single-stranded or double-stranded, and any chemical modifications thereof. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge,

polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

"SELEX" methodology involves the combination of selection of nucleic acid ligands which interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Optional iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids which interact most strongly with the target from a pool which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. In the present invention, the SELEX methodology is employed to obtain nucleic acid ligands to tenascin-C.

The SELEX methodology is described in the SELEX Patent Applications.

"SELEX target" or "target" means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation. In this application, the SELEX target is tenascin-C.

"Complex" as used herein means the molecular entity formed by the covalent linking of one or more tenascin-C nucleic acid ligands with one or more markers. In certain embodiments of the present invention, the complex is depicted as A-B-Y, wherein A is a marker; B is optional, and comprises a linker; and Y is a tenascin-C nucleic acid ligand.

"Marker" as used herein is a molecular entity or entities that when complexed with the tenascin-C nucleic acid ligand, either directly or through a linker(s) or spacer(s), allows the detection of the complex in an *in vivo* or *ex vivo* setting through visual or chemical means. Examples of markers include, but are not limited to radionuclides, including Tc-99m, Re-188, Cu-64, Cu-67, F-18,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{32}\text{P}$ ,  $^{186}\text{Re}$ ; all fluorophores, including fluorescein, rhodamine, Texas Red; derivatives of the above fluorophores, including Rhodamine-Red-X; magnetic compounds; and biotin.

As used herein, "linker" is a molecular entity that connects two or more molecular entities through covalent bond or non-covalent interactions, and can allow spatial separation of the molecular entities in a manner that preserves the functional properties of one or more of the molecular entities. A linker can also be known as a spacer. Examples of a linker  
5 include, but are not limited to, the  $(\text{CH}_2\text{CH}_2\text{O})_6$  and hexylamine structures shown in **Figure 2**.

"Therapeutic" as used herein, includes treatment and/or prophylaxis. When used, therapeutic refers to humans and other animals.

"Covalent Bond" is the chemical bond formed by the sharing of electrons.

10 "Non-covalent interactions" are means by which molecular entities are held together by interactions other than Covalent Bonds including ionic interactions and hydrogen bonds.

In the preferred embodiment, the nucleic acid ligands of the present invention are derived from the SELEX methodology. The SELEX process is described in United States Patent Application Serial No. 07/536,428, entitled "Systematic Evolution of Ligands by  
15 Exponential Enrichment," now abandoned, United States Patent No. 5,475,096, entitled "Nucleic Acid Ligands" and United States Patent No. 5,270,163, (see also WO 91/19813), entitled "Methods for Identifying Nucleic Acid Ligands." These applications, each specifically incorporated herein by reference, are collectively called the SELEX Patent Applications.

20 The SELEX process provides a class of products which are nucleic acid molecules, each having a unique sequence, and each of which has the property of binding specifically to a desired target compound or molecule. Target molecules are preferably proteins, but can also include among others carbohydrates, peptidoglycans and a variety of small molecules. SELEX methodology can also be used to target biological structures, such as cell surfaces or  
25 viruses, through specific interaction with a molecule that is an integral part of that biological structure.

In its most basic form, the SELEX process may be defined by the following series of steps:

30 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: (a) to assist in the amplification steps described below, (b) to mimic a sequence known to bind to the target, or

(c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent).

2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.

3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning.

4) Those nucleic acids selected during partitioning as having the relatively higher affinity for the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.

5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer unique sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.

The basic SELEX method has been modified to achieve a number of specific objectives. For example, United States Patent Application Serial No. 07/960,093, filed October 14, 1992, now abandoned, and United States Patent No. 5,707,796, both entitled "Method for Selecting Nucleic Acids on the Basis of Structure," describe the use of the SELEX process in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA. United States Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled "Photoselection of Nucleic Acid Ligands," now abandoned, United States Patent No. 5,763,177, entitled "Systematic

Evolution of Ligands by Exponential Enrichment: Photoselection of Nucleic Acid Ligands and Solution SELEX" and United States Patent Application Serial No. 09/093,293, filed June 8 1998, entitled "Systematic Evolution of Ligands by Exponential Enrichment:

Photoselection of Nucleic Acid Ligands and Solution SELEX," all describe a SELEX based  
5 method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. United States Patent No. 5,580,737, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine," describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed Counter-SELEX.

10 United States Patent No. 5,567,588, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Solution SELEX," describes a SELEX-based method which achieves highly efficient partitioning between oligonucleotides having high and low affinity for a target molecule. United States Patent No. 5,496,938, entitled "Nucleic Acid Ligands to HIV-RT and HIV-1 Rev," describes methods for obtaining improved nucleic acid ligands  
15 after SELEX has been performed. United States Patent No. 5,705,337 entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chemi-SELEX," describes methods for covalently linking a ligand to its target.

The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand,  
20 such as improved *in vivo* stability or improved delivery characteristics. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. SELEX-identified nucleic acid ligands containing modified nucleotides are described in United States Patent No. 5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," that describes oligonucleotides containing  
25 nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines. United States Patent No. 5,637,459, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH<sub>2</sub>), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). United States Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by  
30 Intramolecular Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines.

The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in United

States Patent No. 5,637,459, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX," and United States Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules.

In United States Patent No. 5,496,938 methods are described for obtaining improved Nucleic Acid Ligands after the SELEX process has been performed. This patent, entitled "Nucleic Acid Ligands to HIV-RT and HIV-1 Rev," is specifically incorporated herein by reference.

United States Patent Application No. 08/434,425, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX," filed May 3, 1995, now United States Patent No. 5,789,157, describes methods for identifying a nucleic acid ligands to a macromolecular component of a tissue, including cancer cells, and the nucleic acid ligands so identified. This patent is specifically incorporated herein by reference.

One potential problem encountered in the diagnostic or therapeutic use of nucleic acids is that oligonucleotides in their phosphodiester form may be quickly degraded in body fluids by intracellular and extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. Certain chemical modifications of the nucleic acid ligand can be made to increase the *in vivo* stability of the nucleic acid ligand or to enhance or to mediate the delivery of the nucleic acid ligand. See, e.g., U.S. Patent Application Serial No. 08/117,991, filed September 8, 1993, now abandoned, and United States Patent No. 5,660,985, both entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," which is specifically incorporated herein by reference. Modifications of the nucleic acid ligands contemplated in this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil; backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications

can also include 3' and 5' modifications such as capping. In preferred embodiments of the instant invention, the nucleic acid ligands are RNA molecules that are 2'-fluoro (2'-F) modified on the sugar moiety of pyrimidine residues.

The modifications can be pre- or post-SELEX process modifications. Pre-SELEX process modifications yield nucleic acid ligands with both specificity for their SELEX target and improved *in vivo* stability. Post-SELEX process modifications made to 2'-OH nucleic acid ligands can result in improved *in vivo* stability without adversely affecting the binding capacity of the nucleic acid ligand.

Other modifications are known to one of ordinary skill in the art. Such modifications may be made post-SELEX process (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.

The nucleic acid ligands of the invention are prepared through the SELEX methodology that is outlined above and thoroughly enabled in the SELEX applications incorporated herein by reference in their entirety.

The tenascin-C aptamers of the invention bind to the heparin binding site of the tenascin-C COOH terminus.

In certain embodiments of the present invention, the nucleic acid ligands to tenascin-C described herein are useful for diagnostic purposes and can be used to image pathological conditions (such as human tumor imaging). In addition to diagnosis, the tenascin-C nucleic acid ligands are useful in the prognosis and monitoring of disease conditions in which tenascin-C is expressed.

Diagnostic agents need only be able to allow the user to identify the presence of a given target at a particular locale or concentration. Simply the ability to form binding pairs with the target may be sufficient to trigger a positive signal for diagnostic purposes. Those skilled in the art would be able to adapt any tenascin-C nucleic acid ligand by procedures known in the art to incorporate a marker in order to track the presence of the nucleic acid ligand. Such a marker could be used in a number of diagnostic procedures, such as detection of primary and metastatic tumors and atherosclerotic lesions. The labeling markers exemplified herein are technetium-99m and <sup>111</sup>In; however, other markers such as additional radionuclides, magnetic compounds, fluorophores, biotin, and the like can be conjugated to the tenascin-C nucleic acid ligand for imaging in an *in vivo* or *ex vivo* setting disease conditions in which tenascin-C is expressed (e.g., cancer, atherosclerosis, and psoriasis). The marker may be covalently bound to a variety of positions on the tenascin-C nucleic acid



ligand, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl group or other group at the 5' or 3' terminus of the tenascin-C nucleic acid ligand. In embodiments where the marker is technetium-99m or  $^{111}\text{In}$ , preferably it is bonded to the 5' or 3' hydroxyl of the phosphate group thereof or to the 5 position of a modified pyrimidine. In the most preferred embodiment, the marker is bonded to the 5' hydroxyl of the phosphate group of the nucleic acid ligand with or without a linker. In another embodiment, the marker is conjugated to the nucleic acid ligand by incorporating a pyrimidine containing a primary amine at the 5 position, and use of the amine for conjugation to the marker. Attachment of the marker can be done directly or with the utilization of a linker. In the embodiment where technetium-99m or  $^{111}\text{In}$  is used as the marker, the preferred linker is a hexylamine linker as shown in Figure 10.

In other embodiments, the tenascin-C nucleic acid ligands are useful for the delivery of therapeutic compounds (including, but not limited to, cytotoxic compounds, immune enhancing substances and therapeutic radionuclides) to tissues or organs expressing tenascin-C. Disease conditions in which tenascin-C may be expressed include, but are not limited to, cancer, atherosclerosis, and psoriasis. Those skilled in the art would be able to adapt any tenascin-C nucleic acid ligand by procedures known in the art to incorporate a therapeutic compound in a complex. The therapeutic compound may be covalently bound to a variety of positions on the tenascin-C nucleic acid ligand, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl group or other group at the 5' or 3' terminus of the tenascin-C nucleic acid ligand. In the preferred embodiment, the therapeutic agent is bonded to the 5' amine of the nucleic acid ligand. Attachment of the therapeutic agent can be done directly or with the utilization of a linker. In embodiments in which cancer is the targeted disease, 5-fluorodeoxyuracil or other nucleotide analogs known to be active against tumors can be incorporated internally into existing U's within the tenascin-C nucleic acid ligand or can be added internally or conjugated to either terminus either directly or through a linker. In addition, both pyrimidine analogues 2'2'-difluorocytidine and purine analogues (deoxycoformycin) can be incorporated. In addition, United States Application Serial No. 08/993,765, filed December 18, 1997, incorporated herein by reference in its entirety, describes, *inter alia*, nucleotide-based prodrugs comprising nucleic acid ligands directed to a

tumor, for example tenascin-C, for precisely localizing chemoradiosensitizers, and radiosensitizers and radionuclides and other radiotherapeutic agents to the tumor.

It is also contemplated that both the marker and therapeutic agent may be associated with the tenascin-C nucleic acid ligand, such that detection of the disease condition and delivery of the therapeutic agent is accomplished together in one aptamer or as a mixture of two or more different modified versions of the same aptamer. It is also contemplated that either or both the marker and/or the therapeutic agent may be associated with a non-immunogenic, high molecular weight compound or lipophilic compound, such as a liposome. Methods for conjugating nucleic acid ligands with lipophilic compounds or non-immunogenic compounds in a diagnostic or therapeutic complex are described in United States Patent Application Serial No. 08/434,465, filed May 4, 1995, entitled "Nucleic Acid Ligand Complexes," which is incorporated herein in its entirety.

The therapeutic or diagnostic compositions described herein may be administered parenterally by injection (e.g., intravenous, subcutaneous, intradermal, intralesional), although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iontophoresis or suppositories, are also envisioned. They may also be applied locally by direct injection, can be released from devices, such as implanted stents or catheters, or delivered directly to the site by an infusion pump. One preferred carrier is physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers may also be used. In one embodiment, it is envisioned that the carrier and the tenascin-C nucleic acid ligand complexed with a therapeutic compound constitute a physiologically-compatible, slow release formulation. The primary solvent in such a carrier may be either aqueous or non-aqueous in nature. In addition, the carrier may contain other pharmacologically acceptable excipients for modifying or maintaining the pH, osmolality, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, release, or absorption of the tenascin-C nucleic acid ligand. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dose or multi-dose form.

Once the therapeutic or diagnostic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in ready to use form or requiring reconstitution immediately prior to administration. The manner of administering formulations containing

tenascin-C nucleic acid ligands for systemic delivery may be via subcutaneous, intramuscular, intravenous, intraarterial, intranasal or vaginal or rectal suppository.

The following examples are provided to explain and illustrate the present invention and are not to be taken as limiting of the invention. Example 1 describes the materials and experimental procedures used in Example 2 for the generation of RNA ligands to tenascin-C. Example 2 describes the RNA ligands to tenascin-C and the predicted secondary structure of a selected nucleic acid ligand. Example 3 describes the determination of minimal size necessary for high affinity binding of a selected nucleic acid ligand, and substitution of 2'-OH purines with 2'-OMe purines. Example 4 describes the biodistribution of Tc-99m labeled tenascin-C nucleic acid ligands in tumor-bearing mice. Example 5 describes the use of a fluorescently labeled tenascin-C nucleic acid ligand to localize tenascin-c within tumor tissue. Example 6 describes detection of tumors *in vivo* by Aptamer TTA1 (also known as GS7641). Example 7 describes alternative labeling using <sup>111</sup>In.

## EXAMPLES

### Example 1. Use of SELEX to obtain nucleic acid ligands to tenascin-C and to U251 glioblastoma cells.

#### Materials and Methods

Tenascin-C was purchased from Chemicon (Temecula, CA). Single-stranded DNA-primers and templates were synthesized by Operon Technologies Inc. (Alameda, CA).

The SELEX-process has been described in detail in the SELEX Patent Applications. In brief, double-stranded transcription templates were prepared by Klenow fragment extension of 40N7a ssDNA:

5'- TCGCGCGAGTCGTCTG [40N] CCGCATCGTCCTCCC 3' (SEQ ID NO:1)

using the 5N7 primer:

5'-TAATACGACTCACTATAGGGGAGGACGATGCGG-3' (SEQ ID NO:2)

which contains the T7 polymerase promoter (underlined). RNA was prepared with T7 RNA polymerase as described previously in Fitzwater and Polisky (1996) *Methods Enzymol.* 267: 275-301, incorporated herein by reference in its entirety. All transcription reactions were performed in the presence of pyrimidine nucleotides that were 2'-fluoro (2'-F) modified on the sugar moiety. This substitution confers enhanced resistance to ribonucleases that utilize the 2'-hydroxyl moiety for cleavage of the phosphodiester bond. Specifically, each transcription mixture contained 3.3 mM 2'-F UTP and 3.3 mM 2'-F CTP along with 1 mM

GTP and ATP. The initial randomized RNA library thus produced comprised  $3 \times 10^{14}$  molecules. The affinities of individual ligands for tenascin-C were determined by standard methods using nitrocellulose filter partitioning (Tuerk and Gold (1990) Science 249(4968):505-10).

5 For each round of SELEX, Lumino plates (Labsystems, Needham Heights, MA) were coated for 2 hours at room temperature with 200  $\mu$ l Dulbecco's PBS containing tenascin-C concentrations as shown in **Table 1**. After coating, wells were blocked using HBSMC+ buffer [20 mM Hepes, pH 7.4, 137 mM NaCl, 1 mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$  and 1 g/liter human serum albumin (Sigma, fraction V) for rounds 1 to 6 while for rounds 7 and 8 wells  
10 were blocked HBSMC+ buffer containing 1 g/liter casein (I-block; Tropix). Binding and wash buffer consisted of HBSMC+ buffer containing 0.05% Tween 20. For each SELEX round, RNA was diluted into 100  $\mu$ l of binding buffer and allowed to incubate for 2 hours at 37°C in the protein coated wells that were pre-washed with binding buffer. After binding, six washes of 200  $\mu$ l each were performed. Following the wash step, the dry well was placed on  
15 top of a 95°C heat block for 5 minutes. Standard AMV reverse transcriptase reactions (50  $\mu$ l) were performed at 48°C directly in the well and the reaction products utilized for standard PCR and transcription reactions. Two synthetic primers 5N7 (see above) and 3N7a: 5'-TCGCGCGAGTCGTCTG-3' (SEQ ID NO:3) were used for these template amplification and reverse transcription steps.

20 For cell SELEX, U251 human glioblastoma cells (Hum. Hered. (1971) 21:238) were grown to confluence in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal calf serum (GIBCO BRL, Gaithersburg, MD) on six-well tissue culture plates (Becton Dickinson Labware, Lincoln Park, NJ) and washed three times using Dulbecco's PBS supplemented with  $\text{CaCl}_2$  (DPBS, GIBCO BRL) buffer. RNA labeled internally by  
25 transcription (Fitzwater (1996) *supra*) was incubated with the cells at 37°C for one hour. The labeled RNA was then removed, and the cells were washed six times for ten minutes each at 37°C with DPBS. DPBS containing 5 mM EDTA was then added and incubated with the cells for 30 minutes to elute bound RNAs that remained after the washing steps. This RNA was quantitated by a standard liquid scintillation counting protocol and amplified using RT-  
30 PCR.

Binding assays for the U251 cells. Internally labeled RNA was incubated at increasing concentrations with confluent U251 cells in six-well tissue culture plates (Becton Dickinson Labware, Lincoln Park, NJ) at 37°C for 60 min. Unbound RNA was washed away

using three 10 minute washes with DPBS+ CaCl<sub>2</sub> at 37°C, and bound RNA was collected by disrupting the cells using Trizol (Gibco BRL, Gaithersburg, MD). Bound RNA was quantitated by liquid scintillation counting.

**Cloning and Sequencing.** Amplified affinity enriched oligonucleotide pools were purified on an 8% polyacrylamide gel, reverse transcribed into ssDNA and the DNA amplified by the polymerase chain reaction (PCR) using primers containing BamHI and HindIII restriction endonuclease sites. PCR fragments were cloned, plasmids prepared and sequence analyses performed according to standard techniques (Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Ed. 3 vols., Cold Spring Harbor Laboratory Press, Cold Spring Harbor).

#### **Example 2. RNA ligands to tenascin-C.**

Nucleic Acid Ligands to U251 cells were obtained by the SELEX process and are described in United States Patent Application Serial No. 08/434,425, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Tissue SELEX," filed May 3, 1995, now United States Patent No. 5,789,157. Subsequently it was determined that the ligands that were obtained were tenascin-C nucleic acid ligands.

To obtain oligonucleotide ligands against human tenascin-C, eight rounds of SELEX were performed using the randomized nucleotide library as described above in Materials and Methods. RNA and protein input into each round is shown in **Table 1**. After 8 rounds of SELEX, the affinity of the oligonucleotide pool for tenascin-C was 10 nM, and this affinity did not increase with additional SELEX rounds.

To obtain ligands to U251 glioblastoma cells, nine rounds of SELEX were performed using the randomized nucleotide library. After nine rounds of binding to U251 cells and EDTA elution, rounds 3, 5 and 9 were tested for their ability to bind to U251 cells. **Figure 1** shows that as the number of SELEX rounds increases, the amount of bound RNA also increases at a particular concentration. Because of the complexity of the target tissue, it was not possible to estimate the affinity of the oligonucleotide pools for the unknown target molecules(s) on these cells.

The E9 pool (nine rounds of binding and EDTA elution from U251 cells) was then used as a starting point for a SELEX against purified tenascin-C. Two rounds of SELEX using purified tenascin-C were performed as described above. Input protein and RNA concentrations for two rounds of SELEX (E9P1 and E9P2) are described in **Table 2**.

In summary, three different SELEX experiments were performed: an experiment using purified tenascin-C as the target, an experiment using U251 glioblastoma cells as the target, and an experiment in which the SELEX pool from the U251 glioblastoma cells was used to initiate a SELEX experiment using purified tenascin-C as the target.

5 All three SELEX experiments were analyzed by cloning and sequencing ligands from round 8 of the purified tenascin-C SELEX ("TN" sequences), from round 9 of the U251 cell SELEX ("E9" sequences), and from round 2 of the U251/tenascin-C hybrid SELEX ("E9P2" sequences). The sequences of 34 unique clones are shown in **Table 3**, and are divided into two major groups: tenascin-C ligands ("TN" and "E9P2" sequences) and U251 cell ligands ("E9" ligands). Among the tenascin-C ligands, the majority of the clones (65 total) represent one of two distinct sequence classes designated Family I and Family II (**Figure 1**).

Examination of the variable region of the 12 clones in Family I revealed 7 unique sequences that are related through the consensus sequence GACNYUCCNGCYAC (SEQ ID NO:12).

Examination of the variable region of the 18 clones in Family II revealed sequences that

15 share a consensus sequence CGUCGCC (**Table 3**). The E9 sequences could be grouped into a related set by virtue of conserved GAY and CAU sequences within the variable regions. The remaining sequences did not appear related to other sequences and were classified as orphans. Three sequences predominate, with E9P2-1, E9P2-2, and TN9 represented 14, 16, and 10 times respectively. In the "Orphan" category, one sequence, TN18, was represented

20 twice. Overall, these data represent a highly enriched sequence pool.

Most individuals displayed low nanomolar dissociation constants, with the three most prevalent sequences, TN9 and E9P2-1 and -2, having the highest affinities at 5 nM, 2 nM, and 8 nM. (**Table 3**). These results indicate that the U251 cell SELEX is a repository for aptamers against tenascin-C, and that only two rounds of SELEX were required to isolate the

### **Example 3. Determination of minimal size of TN9, and substitution of 2'-OH purines with 2'-OMe purines: synthesis of aptamer TTA1.**

30 Oligonucleotide synthesis procedures were standard for those skilled in the art (Green *et al.* (1995) *Chem Biol* 2(10):683-95). 2'-fluoro pyrimidine phosphoramidite monomers were obtained from JBL Scientific (San Luis Obispo, CA); 2'-OMe purine, 2'-OH purine, hexylamine, and (CH<sub>2</sub>CH<sub>2</sub>O)<sub>6</sub> monomers, along with the dT polystyrene solid support, were

obtained from Glen Research (Sterling, VA). Aptamer affinities were determined using nitrocellulose filter partitioning (Green *et al.*, *supra*).

TN9 was chosen for further analysis based on its high affinity for tenascin-C. We first searched for a minimal sequence necessary for high affinity binding. Using standard techniques (Green *et al.*, *supra*), it was discovered that nucleotides 3' of nucleotide 55 were required for binding to tenascin-C, while no nucleotides could be removed from the 5' end without loss of affinity. To further decrease the TN9's length from 55 nucleotides and retain high affinity binding, we then attempted to define internal deletions of TN9. The first 55 nucleotides of TN9, along with the first 55 nucleotides of related family II ligands TN7, TN21, and TN41, were input into a computer algorithm to determine possible RNA secondary structure foldings (mfold 3.0, accessed at <http://www.ibc.wustl.edu/~zucker/>. M. Zuker, D.H. Mathews & D.H. Turner. Algorithms and Thermodynamics for RNA Secondary Structure Prediction: A Practical Guide. In: RNA Biochemistry and Biotechnology, J. Barciszewski & B.F.C. Clark, eds., NATO ASI Series, Kluwer Academic Publishers, (1999)). Among many potential RNA foldings predicted by the algorithm, a structure common to each oligonucleotide was found. This structure, represented by oligonucleotide TTA1 in **Figure 2**, contains three stems that meet at a single junction, a so-called 3-stem junction. This folding places the most highly conserved nucleotides of family II oligonucleotides at the junction area. In comparing TN9, TN7, TN21, and TN41, the second stem was of variable length and sequence, suggesting that extension of the second stem is not required for binding to tenascin-C. Testing this hypothesis on TN9, we found that nucleotides 10-26 could be replaced with an ethylene glycol linker, (CH<sub>2</sub>CH<sub>2</sub>O)<sub>6</sub>. The linker serves as a substitute loop and decreases the size of the aptamer. Additionally, four-nucleotide loops (CACU or GAGA) that replace nucleotides 10-26 produce sequences with high affinity for tenascin-C. It would be well within one skilled in the art to determine other nucleotide loops or other spacers that could replace nucleotides 10-26 to produce sequences with high affinity for tenascin-C.

To increase protection against nuclease activity, purine positions that could be substituted with the corresponding 2'-OMe purines were located. The oligonucleotide was arbitrarily divided into five sectors and all purines within each sector were substituted by the corresponding 2'-OMe purine nucleotide, a total of five oligonucleotides (**Table 4**, Phase I syntheses). The affinity of each oligonucleotide for tenascin-C was determined, and it was found that all purines within sectors 1, 3 and 5 could be substituted without appreciable loss in

affinity. Within sectors 2 and 4, individual purines were then substituted with 2'-OMe purines and the effect of affinity was measured (Table 4, Phase III syntheses). From these experiments, it was deduced that substitution of nucleotides G9, G28, G31, and G34, with 2'-OMe G causes loss in affinity for tenascin-C. Therefore these nucleotides remain as 2'-OH purines in the aptamer TTA1.

The aptamer TTA1 (Table 4) was then synthesized with the (CH<sub>2</sub>CH<sub>2</sub>O)<sub>6</sub> (Spacer 18) linker, a 3'-3' dT cap for exonuclease protection, a 5' hexylamine (Table 4), and all purines as 2'-OMe except the 5 Gs indicated in Table 4. A non-binding control aptamer, TTA1.NB, was generated by deleting 5 nucleotides at the 3' end to produce TTA1.NB. TTA1 binds to tenascin-C with an equilibrium dissociation constant (K<sub>d</sub>) of 5 nM, while TTA1.NB has a K<sub>d</sub> of > 5 μM for tenascin-C.

Nucleotides 10-26 can be replaced by a non-nucleotide ethylene glycol linker. It is therefore likely that TTA1 can be synthesized in two separate pieces, where a break is introduced at the position of the ethylene glycol linker and new 5' and 3' ends are introduced. Subsequent to synthesis, the two molecules will incubated together to allow hybrid formation. This method allows introduction of additional amine groups as well as nucleotides at the new 5' and 3' ends. The new functionalities could be used for bioconjugation. In addition, two-piece synthesis results in increased chemical synthetic yield due to shortening the length of the molecules.

#### Example 4. Biodistribution of Tc-99m labeled aptamers in tumor-bearing mice.

Aptamer biodistribution was tested by conjugating a Tc-99m chelator (Hi<sub>15</sub>; Hilger *et al.* (1998) Tet Lett 39:9403-9406) to the 5' end of the oligonucleotide as shown in Figure 2, and radiolabeling the aptamer with Tc-99m. The aptamer in its Tc-99m labeled form is shown in Figure 10. TTA1 and TTA1.NB were conjugated to Hi<sub>15</sub> at 50 mg/ml aptamer in 30% dimethylformamide with 5 molar equivalents of Hi<sub>15</sub>-N-hydroxysuccinimide, buffered in 100 mM Na Borate pH 9.3, for 30 minutes at room temperature. The aptamer in its Tc-99m labeled form is shown in Figure 10. Reversed phase HPLC purification yielded Hi<sub>15</sub>-TTA1 and Hi<sub>15</sub>-TTA1.NB. The oligonucleotides were then labeled with Tc-99m in the following manner: to 1 nmole Hi<sub>15</sub>-aptamer was added 200 μL of 100 mM sodium phosphate buffer, pH 8.5, 23 mg/mL NaTartrate, and 50 μL Tc-99m pertechnetate (5.0 mCi) eluted from a Mo-99 column (Syncor, Denver) within 12 hours of use. The labeling reaction was initiated by



the addition of 10  $\mu$ L 5 mg/mL  $\text{SnCl}_2$ . The reaction mixture was incubated for 15 minutes at 90° C. The reaction was separated from unreacted Tc-99m by spin dialysis through a 30,000 MW cut-off membrane (Centrex, Schleicher & Scheull) with two 300  $\mu$ L washes. This labeling protocol results in 30-50% of the added 99mTc being incorporated with a specific activity of 2-3 mCi/nmole RNA. The Tc-99m is bound through the 5'G as shown in Figure 5.

For biodistribution experiments, U251 xenograft tumors were prepared as follows: U251 cells were cultured in Dulbeccos' Modified Eagle's Medium supplemented with 10% v/v fetal calf serum (Gibco BRL, Gaithersburg, MD). Athymic mice (Harlan Sprague Dawley, Indianapolis, IN) were injected subcutaneously with  $1 \times 10^6$  U251 cells. When the tumors reached a size of 200-300 mg (1-2 weeks), Tc-99m labeled aptamer was injected intravenously at 3.25 mg/kg. At indicated times, animals were anesthetized using isoflurane (Fort Dodge Animal Health, Fort Dodge, IA), blood was collected by cardiac puncture, and the animal was sacrificed and tissues were harvested. Tc-99m levels were counted using a gamma counter (Wallac Oy, Turku, Finland). Aptamer uptake into tissues was measured as the % of injected dose per gram of tissue (%ID/g).

Images of mice were obtained using a gamma camera. Mice were placed onto the camera (Siemens, LEM+) under anesthesia (isoflurane). Data were collected (30 sec to 10 minutes) and analyzed using Nuclear MAC software version 3.22.2 (Scientific Imaging, CA) on a Power MAC G3 (Apple Computer, CA).

Biodistribution experiments, Table 5, indicated rapid and specific uptake of the aptamer into tumor tissue; the non-binding aptamer does not remain in the tumor. Blood levels of Tc-99m also cleared rapidly. After three hours, Tc-99m levels brought into the tumor using  $\text{Hi}_{15}$ -TTA1 had a very long half life (> 18 hrs). This indicates that once the aptamer penetrates the tumor, the radiolabel carried with it remains in the tumor for long periods of time. Such data indicate that cytotoxic agents, including radionuclides and non-radioactive agents, conjugated to the aptamer will also remain in the tumor with long half lives.

Tc-99m radioactivity also appears in other tissues, notably the small and large intestines. The hepatobiliary clearance pattern seen here can be readily altered by those skilled in the art, for example by altering the hydrophilicity of the Tc-99m chelator, changing the chelator, or changing the radiometal/chelator pair altogether.

Whole animal images were obtained using Tc-99m labeled Hi<sub>15</sub>-TTA1 and at 3 hours post-injection. Images obtained from mice injected with Hi<sub>15</sub>-TTA1, but not from mice injected with Hi<sub>15</sub>-TTA1.NB, clearly show the tumor (**Figure 3**). Additional radioactivity is evident in gastrointestinal tract, as predicted by the biodistribution experiments.

5

**Example 5. Use of fluorescently labeled TTA1 to localize tenascin-C within tumor tissue.**

**Materials and Methods.**

TTA1 and TTA1.NB were synthesized as described above. Succinimidyl Rhodamine-Red-X (Molecular Probes, Eugene, OR) was conjugated to the 5' amine of the aptamers as described above for H<sub>15</sub>-NHS conjugation. The Rhodamine-Red-X-conjugated aptamers, TTA1-Red and TTA1.NB-Red, were purified by reversed phase HPLC. U251 cell culture and tumor growth in nude mice were as described above. Five nmol of TTA1-Red or TTA1.NB-Red were injected intravenously into nude mice and at the desired time the animal was placed under anesthesia, perfused with 0.9% NaCl, and sacrificed. The tumor was excised and placed in formalin. After 24 hr in formalin, 10  $\mu$ M sections were cut and Rhodamine-Red-X was detected using a fluorescence microscope (Eclipse E800, Nikon, Japan).

Results: TTA1-Red has identical affinity for tenascin-C as the unconjugated parent aptamer, TTA1, at 5 nM. We compared tumor fluorescence levels of TTA1-Red and TTA1.NB-Red 10 min post-injection. The binding aptamer, TTA1-Red, strongly stains the tumor but not adjacent tissue (**Figure 4**). In contrast, only tissue auto-fluorescence is detected with TTA1.NB-Red. These results demonstrate the utility of the aptamer in fluorescent detection of tenascin-C *in vivo*, and the aptamer may be similarly used for staining tissues sections *ex vivo*.

**Example 6. Detection of Tumors *In Vivo* by Aptamer TTA1 (now also known as GS7641): additional tumor types.**

Aptamer labeling, biodistribution, and nude mouse tumor xenografts were performed as described in Example 4.

Many human tumor types are known to express tenascin-C. To assess the ability of TTA1/GS7641 to target tumor types in addition to glioblastomas, human tumor cell lines were grown as tumors in nude mice. Tumor tissue was tested for expression of human

tenascin-C, and those tumors expressing human tenascin-C were tested for aptamer uptake. **Figure 6** demonstrates aptamer uptake in several tumors, including glioblastoma, breast, colorectal, and rhabdomyosarcoma. Specific uptake into the tumor is demonstrated by the comparison between binding (TTA1/GS7641) and non-binding aptamer (TTA1.NB). Note that KB, a xenograft that expresses mouse but not human TN-C, does not show tumor uptake. This experiment extends the observation of glioblastoma uptake into additional carcinomas and sarcomas, and further indicates that all tumors expressing human tenascin-C show uptake of TTA1/GS7641.

#### Example 7. Alternative Labeling Using In-111.

Tumor xenograft and biodistribution studies were performed as described in Example 4. To couple DTPA and DOTA to TTA1/GS7641, the cyclic anhydride of each was incubated with the amine-containing TTA1/GS7641 under neutral pH conditions using standard methods. The structures of the DTPA and conjugates are shown in **Figure 8** and **Figure 9**, respectively, where each has been labeled with In-111. The DOTA conjugate has the identical linkers as for DTPA. DOTA- and DTPA-conjugates were labeled with In-111 by incubation at 95°C in 0.5 M NaOAc, pH 5.5 for 30 min. After removal of unincorporated radiolabel by spin dialysis over a 30K cut-off membrane, radiolabeled aptamer was transferred into phosphate-buffered saline for injection into tumor-bearing mice.

The biodistribution of In-111 labeled aptamer is markedly different from the Tc-labeled formulation described in Example 4. **Figure 7** shows that, relative to Tc-99m-labeled TTA1/GS7641, In-111-labeled TTA1/GS7641 radioactivity in the intestines is greatly reduced, with a concomitant increase in liver and kidney uptake. This experiment indicates that the chemical properties of the chelator have a large effect on distribution of the radiolabel of TTA1/GS7641 within a living animal. Biodistribution patterns that are different from that of <sup>111</sup>In-TTA1/GS7641 may be useful for targeting tumors under certain clinical conditions where hepatobiliary clearance is undesired. Such conditions include but are not limited to radiotherapy applications as well as imaging of intestines, prostate and other abdominal regions.

Table 1. Tenascin-C SELEX RNA and protein input.

	<b>Tenascin-C</b>	<b>RNA</b>
<b>Round</b>	(pMol/well)	(pMol/well)
1	12	200
2	12	200
3	12	200
4	12	200
5	2	33
6	2	33
7	2	33
8	0.2	3.3

5 Table 2. Cell SELEX/tenascin-C SELEX RNA and protein input

	<b>Tenascin-C</b>	<b>RNA</b>
<b>Round</b>	(pMol/well)	(pMol/well)
E9P1	2	33
E9P2	2	33

Table 3: Tenascin-C Sequences: purified protein SELEX (tenascin sequences) and U251 cell SELEX+purified protein SELEX (E9P2 sequences)

Family I

SEQ ID NO:

TN11	4	ggGAggAcGauGcgg	CAAUCAAAACUCACGUUA UUUCC UCAUCUAUUAGCUUCCC	cagacgacucgccccga	10 nM
TN45	5	gggaggacgaugcgg	CAAUUCGAAAGAGACUCUUCU GCAUCCUCUcACCCCC	cagacgacucgccccga	30 nM
TN4	6	gggaggacgaugcgg	CAACCUC GAAAGACUUUUCCC GCAUCACUGUGUACUCCCC	cagacgacucgccccga	40 nM
TN22	7	gggaggacgaugcgg	CAACCUC GAUAGACUUUUCCC GCAUCACUGUGUACUCCCC	cagacgacucgccccga	40 nM
TN32 (2)	8	gggAggAcGauGcgg	cAaCCUcAA UCuUGaCAUUUCCC GcACCUAAAUUUG CCCC	cagacgacucgccccga	15 nM
TN14	9	gggaggacgaugcgg	CAACGAUC ACU UACCUUUCU GCAUCUGCUAGC CUCCCC	cagacgacucgccccga	20 nM
TN44 (3)	10	gggaggacgaugcgg	ACGCCAGCCAUUGACCCUCGCUUCCACUAUCCAUCCCC	cagacgacucgccccga	10 nM
TN29 (2)	11	gggaggacgaugcgg	CCAACCUCAUUUUGACACUUCGCCGACCUAAUUGCCCC	cagacgacucgccccga	25 nM
consensus:	12		GACNYUUCN GCAYC		

Family II

E9P2-4 (5)	13	gggaggacgaugcgg	AACCCUA ACGCGA ACCGACCAACAUCCUCCCGUGCCCC	cagacgacucgccccga	2 nM
E9P2-1 (14)	14	gggAggacgaugcgg	UGCCCAUAG AAGCGU GCCGCUAAUGCUAACGCCUCCCC	cagacgacucgccccga	8 nM
E9P2-2 (16)	15	gggaggacgaugcgg	UGCCACU AUGCGU GCCGAAAAACAUUUCCCUUACCC	cagacgacucgccccga	20 nM
TN7 (3)	16	gggaggacgaugcgg	AACACUUUCCAUUGGUGGCC AUACC GGAUAAUUGUCC	cagacgacucgccccga	10 nM
TN21 (4)	17	gggaggacgaugcgg	ACUGGACCAACCGUGCCGCGGUAU GGAUUAUUGCUCC	cagacgacucgccccga	5 nM
TN9 (10)	18	gggaggacgaugcgg	AACAAUGCACUGCGCGGUAU GGAUUAUUGCUCCUG	cagacgacucgccccga	20 nM
TN41	19	gggaggacgaugcgg	UUAAAGUCUCGGUUGAAU GCCCAUCC AGAUCCCCUGACC	cagacgacucgccccga	
consensus:			GGUGGCGG		

Orphans

E9P2-17	20	gggaggacgaugcgg	AUGGCAAGUCGAACCAUCCCCACCGCUUCUCCUGUUC	cagacgacucgccccga	
E9P2-48	21	gggaggacgaugcgg	GAAUUUUcUCUGCCUUGUUUCGAUUGGCGCCUcccc	cagacgacucgccccga	
E9P2-14	22	gggaggacgaugcgg	UCGAGCGgUCGACCGUCAACAAGAAUAAAGCGUGUCCUG	cagacgacucgccccga	
E9P2-17	23	gggaggacgaugcgg	AUGGCAAGUCGAACCAUCCCCACCGCUUCUCCUGUUC	cagacgacucgccccga	
E9P2-22	24	gggaggacgaugcgg	ACUAGACcgCGAGUCCAUCAUUGCCCCAAAACUCCCC	cagacgacucgccccga	
E9P2-40	25	gggaggacgaugcgg	GAGAUCAACAUUCCUCUAGUUUGGUUCCACCUACACCCC	cagacgacucgccccga	
E9P2-41	26	gggaggacgaugcgg	ACGAGCGUCUCAUGAUCACACUAUUUGUCUCACAGUGCA	cagacgacucgccccga	
TN18	27	gggaggacgaugcgg	UCGACCUUGAAUGACUCCACCUAUCUAACAUCUCCCC	cagacgacucgccccga	145 nM

Table 3 (Continued)

TN20	28	gggaggacgaugcgg	UCGACCUGGAAUGACUCUCCACCUAUCUAAACAGCCUUC	cagacgacucgcccga
TN51	29	gggaggacgaugcgg	AGAACUCAUCCUAAACCGCUCUAACAAAUUCUUGCCGACCG	cagacgacucgcccga
TN8	30	gggaggacgaugcgg	AUAUUcGACACCAACAGGUCCCGGAAAUCAUCCUCUG	cagacgacucgcccga
TN27	31	gggaggacgaugcgg	AAACCAACCGUUGACAC CUUUUGUUUCCGGAAGUCCC	cagacgacucgcccga
TN39	32	gggaggacgaugcgg	AAGCCAACCCUCUAGUCAGCCUUUCGUUCCCACGCCACC	cagacgacucgcccga
TN24	33	gggaggacgaugcgg	gACCAACUAAACUGUUCGAAAGCGUGGaACAUGUCCUGACGC	cagacgacucgcccga
TN5	34	gggaggacgaugcgg	ACCAACUAAACUGUUCGAAAGCGUGGaACACGUCCUGACGC	cagacgacucgcccga
TN36	35	gggaggacgaugcgg	ACCAACUAAACUGUUCGAAAGCGUGGaACACGUCCUGACGC	cagacgacucgcccga
TN6	36	gggaggacgaugcgg	ACCAACUAAACUGUUCGAAAGCGUGGaACACGUCCUGACGC	cagacgacucgcccga
TN10	37	gggaggacgaugcgg	ACCAACUAAACUGUUCGAAAGCGUGGaACACGUCCUGACGC	cagacgacucgcccga
TN1	38	gggaggacgaugcgg	AAGUUUA GuGUCCAGUUCGACACUCCUcUACUCAGCCC	cagacgacucgcccga
TN109	39	gggaggacgaugcgg	AgCCAGAGCCUcUcAGUUCUaCAGAACUuACCCACUGG	cagacgacucgcccga
TN110	40	gggaggacgaugcgg	ACCUAACUCAUACAGGAACCAACCUAGCACUCUCAUGGC	cagacgacucgcccga

U251 SELEX Aptamers, EDTA Elution (E9)

E9-8 (3)	41	gggaggacgaugcgg	GAGAUACAUAUCCUCUAGUUUGGUUCCAACCUACACCCC	cagacgacucgcccga
E9-15	42	gggaggacgaugcgg	AUCUCGAUCCUUCAGCACUUCAUUUCAUUCCUUUcUGCCC	cagacgacucgcccga
E9-6	43	gggaggacgaugcgg	ACGAUCCUUCCUUAA CAUUUCAUAUUUCUUUGUCCC	cagacgacucgcccga
E9-5 (2)	44	gggaggacgaugcgg	UGACGACAACUCGACUG CAUAUCUACAACUCCUGUGCCC	cagacgacucgcccga
E9-3 (6)	45	gggaggacgaugcgg	ACUAGACCGGAGUC CAUUCACUUGCCCCAAAACCUCCCC	cagacgacucgcccga
E9-9	46	gggaggacgaugcgg	GCGCAUCGAGCAACAUCGGAUUCGGAUUCUCCACUCCCC	cagacgacu gcccga

Table 4: 2'-OMe Substitutions, Internal Deletions, TTA1, and TTA1.NB

Phase I. 2'-OMe. Affinity.		Kd.
Sequence	SEQ ID NO:	
TN9.3	47	>10 uM
TN9.4	48	2 nM
TN9.4M1	49	6 nM
TN9.4M2	50	20 nM
TN9.4M3	51	7 nM
TN9.4M4	52	nb
TN9.4M5	53	4 nM
TN9.4Me	54	10 nM

6=mG; 7=mA; 5=3'-3' Cap, l = hexylamine

## Phase III. 2'-OMe. Affinity.

TN9.4M1235	55	16667667C67U6C6677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	16.5 nM
TN9.4M135G6	56	1666766ACGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	2.2 nM
TN9.4M135A7	57	166676GZCGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	1.7 nM
TN9.4M135G9	58	166676GACG6AUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	7.7 nM
TN9.4M135A10	59	166676GACGZUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	1.3 nM
TN9.4M135G12G14	60	166676GACGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	2.5 nM
TN9.4M135G28	61	166676GACGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	37 nM
TN9.4M135G31	62	166676GACGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	55 nM
TN9.4M135G34	63	166676GACGAUGCG677C77U6C7CUCGUCGCCGU77U667U6UUUU6CUCCCU65	7 nM
TTA1:	64	5' - 1G667667CG- (CH <sub>2</sub> CH <sub>2</sub> O) <sub>6</sub> - CGUCGCCGU77U667U6UUUU6CUCCCU65	5 nM
TTA1.NB:	65	5' - 1G667667CG- (CH <sub>2</sub> CH <sub>2</sub> O) <sub>6</sub> - CGUCGCCGU77U667U6UUUU6CU5	>5 uM

Table 5: Biodistribution of Tc-99m-TTA1 and -TTA1.NB

	TTA1		TTA1.NB		min	TTA1	TTA1.NB	
	min		min					
tumor	2	4.470 ± 0.410	4.510 ± 0.300	kidney	2	44.430 ± 4.280	54.470 ± 1.210	
	10	5.940 ± 0.590	3.020 ± 0.210		10	18.810 ± 0.940	14.320 ± 2.080	
	60	2.689 ± 0.310	0.147 ± 0.018		60	1.514 ± 0.040	0.637 ± 0.111	
	180	1.883 ± 0.100	0.043 ± 0.004		180	0.286 ± 0.028	0.221 ± 0.021	
	570	1.199 ± 0.066	0.018 ± 0.001		570	0.140 ± 0.006	0.100 ± 0.013	
	1020	1.150 ± 0.060	N/A		1020	0.081 ± 0.005	N/A	
blood	2	18.247 ± 1.138	15.013 ± 0.506	sm. int.	2	3.690 ± 0.250	3.120 ± 0.100	
	10	2.265 ± 0.245	2.047 ± 0.195		10	7.010 ± 0.070	6.440 ± 0.250	
	60	0.112 ± 0.003	0.102 ± 0.019		60	15.716 ± 2.036	14.649 ± 0.532	
	180	0.032 ± 0.001	0.034 ± 0.003		180	1.479 ± 0.710	1.243 ± 0.405	
	570	0.013 ± 0.001	0.011 ± 0.001		570	0.219 ± 0.147	0.159 ± 0.067	
	1020	0.006 ± 0.001	N/A		1020	0.280 ± 0.243	N/A	
lung	2	8.970 ± 1.210	8.130 ± 0.960	lg. int.	2	2.340 ± 0.240	2.280 ± 0.180	
	10	2.130 ± 0.080	1.940 ± 0.230		10	0.890 ± 0.040	0.770 ± 0.070	
	60	0.157 ± 0.011	0.120 ± 0.005		60	10.799 ± 5.381	21.655 ± 11.676	
	180	0.048 ± 0.006	0.041 ± 0.003		180	26.182 ± 7.839	18.023 ± 3.485	
	570	0.028 ± 0.006	0.017 ± 0.002		570	1.263 ± 0.706	0.716 ± 0.179	
	1020	0.007 ± 0.001	N/A		1020	0.298 ± 0.167	N/A	
liver	2	9.120 ± 0.530	7.900 ± 0.350	muscle	2	1.270 ± 0.130	1.490 ± 0.050	
	10	12.460 ± 1.250	9.100 ± 0.830		10	0.870 ± 0.090	1.840 ± 1.000	
	60	1.234 ± 0.091	0.423 ± 0.095		60	0.064 ± 0.003	0.050 ± 0.004	
	180	0.401 ± 0.084	0.211 ± 0.059		180	0.016 ± 0.002	0.011 ± 0.001	
	570	0.104 ± 0.017	0.058 ± 0.003		570	0.011 ± 0.002	0.007 ± 0.001	
	1020	0.075 ± 0.003	N/A		1020	0.003 ± 0.0003		
spleen	2	5.100 ± 0.410	4.860 ± 0.130					
	10	2.460 ± 0.210	1.220 ± 0.120					
	60	0.643 ± 0.076	0.110 ± 0.015					
	180	0.198 ± 0.026	0.038 ± 0.005					
	570	0.062 ± 0.004	0.020 ± 0.001					
	1020	0.030 ± 0.003	N/A					



What is claimed is:

1. A nucleic acid ligand to tenascin-C identified according to the method comprising:

a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be  
5 partitioned from the remainder of the candidate mixture;  
b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to  
10 tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified.

2. The nucleic acid ligand of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

3. The nucleic acid ligand of claim 2 wherein said single stranded nucleic acids are ribonucleic acids.

4. The nucleic acid ligand of claim 3 wherein said candidate mixture of nucleic acids  
15 comprises 2'-F (2'-fluoro) modified ribonucleic acids.

5. A purified and isolated non-naturally occurring nucleic acid ligand to tenascin-C.

6. The purified and isolated non-naturally occurring nucleic acid ligand of claim 5  
wherein said nucleic acid ligand is single stranded.

7. The purified and isolated non-naturally occurring nucleic acid ligand of claim 6  
20 wherein said nucleic acid ligand is RNA.

8. The purified and isolated non-naturally occurring RNA ligand of claim 7 wherein said ligand is comprised of 2'-fluoro (2'-F) modified nucleotides.

9. The purified and non-naturally occurring RNA ligand of claim 8 wherein said  
25 ligand is selected from the group consisting of the sequences as set forth in Tables 3 and 4 and Figure 2.

10. A method of identifying nucleic acid ligands to tenascin-C, the method comprising:

a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic  
30 acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified.

11. The method of claim 10 further comprising:

5 d) repeating steps a), b), and c).

12. The method of claim 10 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

13. The method of claim 12 wherein said single stranded nucleic acids are ribonucleic acids.

10 14. The method of claim 13 wherein said nucleic acids are 2'-F (2'- fluoro) modified ribonucleic acids.

15. A complex for use in *in vivo* diagnostics comprising a tenascin-C nucleic acid ligand and a marker.

15 16. The complex of claim 15 wherein said tenascin-C nucleic acid ligand is identified by the method comprising:

a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

20 b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C may be identified.

25 17. The complex of claim 16 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

18. The complex of claim 17 wherein said single stranded nucleic acids are ribonucleic acids.

19. The complex of claim 18 wherein said candidate mixture of nucleic acids comprises 2'-F (2'-fluoro) modified ribonucleic acids.

30 20. The complex of claim 15 wherein said marker is selected from the group consisting of radionuclides, fluorophores, magnetic compounds, and biotin.



34

26. A method for the preparation of a complex comprised of a tenascin-C nucleic acid ligand and a marker, said method comprising:

a) contacting a candidate mixture of nucleic acids with tenascin-C, wherein nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be  
5 partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;

c) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acids with relatively higher affinity and specificity for binding to  
10 tenascin-C; and

d) covalently linking said identified tenascin-C nucleic acid ligand with a marker.


27. The method of claim 26 wherein said marker is selected from the group consisting of radionuclides, fluorophores, magnetic compounds, and biotin.

28. The method of claim 27 wherein said radionuclide is selected from the group  
15 consisting of Tc-99m, Re-188, Cu-64, Cu-67, F-18,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{32}\text{P}$ , and  $^{186}\text{Re}$ .

29. The method of claim 28 wherein said marker is Tc-99m.

30. The method of claim 29 further comprising a linker.

31. The complex of claim 30, wherein said linker has the structure




20

25

35

32. The complex of claim 31, wherein said complex is



- 5           33. A method for detecting the presence of a disease that is expressing tenascin-C in a biological tissue which may contain said disease comprising;
- a) identifying a nucleic acid ligand from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of tenascin-C, by the method comprising
- i) contacting a candidate mixture of nucleic acids with tenascin-C, wherein
- 10   nucleic acids having an increased affinity to tenascin-C relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
- ii) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture;
- iii) amplifying the increased affinity nucleic acids to yield a mixture of
- 15   nucleic acids with relatively higher affinity and specificity for binding to tenascin-C, whereby a nucleic acid ligand of tenascin-C is identified;
- b) attaching a marker that can be used in *in vivo* diagnostics to said nucleic acid ligand identified in step iii) to form a marker-nucleic acid ligand complex;
- c) exposing a tissue which may contain said tumor to said marker-nucleic acid ligand
- 20   complex; and

36

d) detecting the presence of said marker-nucleic acid ligand in said tissue, whereby a disease expressing tenascin-C is identified.


34. The method of claim 33 wherein said marker-nucleic acid ligand further comprises a linker.

35. The method of claim 34 wherein said marker is selected from the group consisting of radionuclides, fluorophores, magnetic compounds, and biotin.


36. The method of claim 35 wherein said radionuclide is selected from the group consisting of Tc-99m, Re-188, Cu64, Cu67, F-18,  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  $^{32}\text{P}$ , and  $^{186}\text{Re}$ .

37. The method of claim 36 wherein said marker is technetium-99m.

38. The method of claim 37 wherein said linker



39. The method of claim 38 wherein said marker-nucleic acid ligand is



All A's = 2'-OMe

All Gs, except as indicated, are 2'-OMe modified

All Cs are 2'-F modified

All Us are 2'-F modified

40. The method of claim 33 further comprising attaching a therapeutic or diagnostic agent to said complex.

5 41. The method of claim 33 wherein said disease is selected from the group consisting of cancer, psoriasis, and atherosclerosis.

42. The method of claim 41 wherein said disease is cancer.

43. A method for delivering a therapeutic agent to a disease that is expressing tenascin-C comprising:

10 covalently linking a tenascin-C nucleic acid ligand with a therapeutic agent to form a complex, and administering said complex to a patient.

10/031193  
531 Rec'd PCT/A 15 JAN 2002

# ABSTRACT

Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.



10/031193

531 Rec'd PCT/F 15 JAN 2002

Express Mail No. EV 001126254 US  
Docket No. NEX86/PCT-US

**IN THE UNITED STATES RECEIVING OFFICE  
(RO/US)**

U.S. APPLICATION SERIAL NO.: 10/ \_\_\_\_\_

U.S. FILING DATE: JANUARY 15, 2002

INTERNATIONAL APPLICATION NO.: PCT/US00/02167

INTERNATIONAL FILING DATE: 28 JANUARY 2000

PRIORITY DATE CLAIMED: 29 JULY 1999

FOR: TENASCIN-C NUCLEIC ACID LIGANDS

APPLICANT: GILEAD SCIENCES, INC.

Assistant Commissioner for Patents  
Washington, D.C. 20231  
BOX: PCT  
Attention: RO/US

**STATEMENT UNDER 37 C.F.R. § 1.821(f)**

Dear Sir:


Enclosed is a computer readable form of the SEQUENCE LISTING for the above-identified application submitted under 37 C.F.R. § 1.821(e). A paper copy of the SEQUENCE LISTING has been submitted under 37 C.F.R. § 1.821(c).

I hereby state that the contents of the disk and the paper copy are the same. 37 C.F.R. § 1.821(f).

The paper and disk copies of the SEQUENCE LISTING include no new matter. 37 C.F.R. § 1.821(g).

Respectfully submitted,

Date: January 16, 2002

  
Rosemary Kellogg, #39,726  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129  
Telephone: (303) 268-0066  
Facsimile: (303) 268-0065

1/8




FIGURE 1

2/8




FIGURE 2

3/8




FIGURE 3

4/8




FIGURE 4

5/8




FIGURE 5

6/8




FIGURE 6




FIGURE 7

7/8




FIGURE 8




FIGURE 9



8/8




FIGURE 10

DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION

Page 1 of 2  
Docket No. NEX86/PCT-US

As a below named inventor, I hereby declare that:  
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the sole, original and first inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled  
**TENASCIN-C NUCLEIC ACID LIGANDS**, the specification of which:

- ☐ is attached hereto.  
☒ was filed on **January 28, 2000** as United States Application Serial No. \_\_\_\_\_ or PCT International Application  
Number **PCT/US00/02167** and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 USC §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number: \_\_\_\_\_ Country: \_\_\_\_\_ Date Filed: (day/mo/yr) \_\_\_\_\_ Priority not claimed ☐  
I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_

I hereby claim the benefit under 35 USC §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

- Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_ Status - patented, pending, abandoned  
09/364,902 07/29/99 Patented  
I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

✓ Barry J. Swanson, #33,215  
Thomas D. Bratschun, #32,966  
Steven N. Hird, #P-51-112

Rosemary Kellogg, #39,726  
Margaret M. Wall, #33,462

Darla G. Yoerg, #48,053  
James L. Brown, #48,576

Address all telephone calls to:  
Address all correspondence to:

at telephone number 303-268-0066 (Customer No.: 25871)  
Customer No.: 25871  
Barry J. Swanson  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): **Brian Hicke**

Inventor's signature: Brian Hicke  
Residence: Boulder, Colorado CO  
Post Office Address: 3255 6<sup>th</sup> Street  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA

Date: 1/13/02  
Citizenship: US

- ☒ Additional inventors are being named on separately numbered sheets attached hereto.

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

Page 1 of 2  
Docket No. NEX86/PCT-US

As a below named inventor, I hereby declare that:  
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the sole, original and first inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled  
**TENASCIN-C NUCLEIC ACID LIGANDS**, the specification of which:

- ☐ is attached hereto.  
☒ was filed on **January 28, 2000** as United States Application Serial No. \_\_\_\_\_ or **PCT International Application**  
**Number PCT/US00/02167** and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.  
I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.  
I hereby claim foreign priority benefits under 35 USC §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.  
Prior Foreign Application(s)

Number: \_\_\_\_\_ Country: \_\_\_\_\_ Date Filed: (day/mo/yr) \_\_\_\_\_ Priority not claimed ☐  
I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_  
I hereby claim the benefit under 35 USC §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_ Status - patented, pending, abandoned  
09/364,902 07/29/99 Patented  
I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Barry J. Swanson, #33,215	Rosemary Kellogg, #39,726	Darla G. Yoerg, #48,053
Thomas D. Bratschun, #32,966	Margaret M. Wall, #33,462	James L. Brown, #48,576
Steven N. Hird, #P-51-112		

Address all telephone calls to: at telephone number 303-268-0066 (Customer No.: 25871)  
Address all correspondence to: Customer No.: 25871  
Barry J. Swanson  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): **Brian Hicke**

Inventor's signature: \_\_\_\_\_ Date: \_\_\_\_\_  
Residence: Boulder, Colorado Citizenship: US  
Post Office Address: 3255 6<sup>th</sup> Street  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA

- ☒ Additional inventors are being named on separately numbered sheets attached hereto.

Full name of second joint inventor (given name, family name): **Stephen Warren**

Inventor's signature: *Stephen Warren*  
Residence: Boulder, Colorado CO  
Post Office Address: 1095 Uttica Avenue  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA

Date: 01-22-02  
Citizenship: US

Full name of third joint inventor (given name, family name): **David Parma**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 6140 Habitat Drive  
Boulder, Colorado 80301  
UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

Full name of fourth joint inventor (given name, family name): **Larry Gold**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 1033 5<sup>th</sup> Street  
Boulder, Colorado 80302  
UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

S:\Client Folders\NeXstar\Nex86\PCT\US\Declaration.doc

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION**

Page 1 of 2  
Docket No. NEX86/PCT-US

As a below named inventor, I hereby declare that:  
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the sole, original and first inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled  
**TENASCIN-C NUCLEIC ACID LIGANDS**, the specification of which:

- ☐ is attached hereto.  
☒ was filed on **January 28, 2000** as United States Application Serial No. \_\_\_\_\_ or **PCT International Application**  
**Number PCT/US00/02167** and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 USC §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number: \_\_\_\_\_ Country: \_\_\_\_\_ Date Filed: (day/mo/yr) \_\_\_\_\_ Priority not claimed ☐

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_

I hereby claim the benefit under 35 USC §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Number: \_\_\_\_\_ Filing Date: (mo/day/yr) \_\_\_\_\_ Status - patented, pending, abandoned  
09/364,902 07/29/99 Patented

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Barry J. Swanson, #33,215  
Thomas D. Bratschun, #32,966  
Steven N. Hird, #P-51-112

Rosemary Kellogg, #39,726  
Margaret M. Wall, #33,462

Darla G. Yoerg, #48,053  
James L. Brown, #48,576

Address all telephone calls to:  
Address all correspondence to:

at telephone number 303-268-0066 (Customer No.: 25871)  
Customer No.: 25871  
Barry J. Swanson  
Swanson & Bratschun, L.L.C.  
1745 Shea Center Drive, Suite 330  
Highlands Ranch, Colorado 80129

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): **Brian Hicke**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 3255 6<sup>th</sup> Street  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

☒ Additional inventors are being named on separately numbered sheets attached hereto.

Full name of second joint inventor (given name, family name): **Stephen Warren**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 1095 Uttica Avenue  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

Full name of third joint-inventor (given name, family name): **David Parma**

Inventor's signature: Edward Hanna  
 Residence: Boulder, Colorado  
 Post Office Address: 6140 Habitat Drive 13860 COAKLEAF Cn  
Boulder, Colorado 80304 DrP  
UNITED STATES OF AMERICA

Date: 01/09/02  
Citizenship: US

Full name of fourth joint inventor (given name, family name): **Larry Gold**

Inventor's signature: \_\_\_\_\_  
 Residence: Boulder, Colorado  
 Post Office Address: 1033 5<sup>th</sup> Street  
 Boulder, Colorado 80302  
 UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

S:\Client Folders\NeXstar\Nex86\PCT\US\Declaration.doc

Full name of second joint inventor (given name, family name): **Stephen Warren**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 1095 Uttica Avenue  
Boulder, Colorado 80304  
UNITED STATES OF AMERICA


Date: \_\_\_\_\_  
Citizenship: US

Full name of third joint inventor (given name, family name): **David Parma**

Inventor's signature: \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 6140 Habitat Drive  
Boulder, Colorado 80301  
UNITED STATES OF AMERICA

Date: \_\_\_\_\_  
Citizenship: US

Full name of fourth joint inventor (given name, family name): **Larry Gold**

400  
Inventor's signature:  \_\_\_\_\_  
Residence: Boulder, Colorado  
Post Office Address: 1033 5<sup>th</sup> Street  
Boulder, Colorado 80302  
UNITED STATES OF AMERICA

Date: 11/13/02  
Citizenship: US

## SEQUENCE LISTING

10 ROSE 15 JAN 2002

&lt;110&gt; NeXstar Pharmaceuticals, Inc.

&lt;120&gt; Tenascin-C Nucleic Acid Ligands

&lt;130&gt; NEX 86/PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 09/364,902

&lt;151&gt; 1999-07-29

&lt;160&gt; 65

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 71

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;400&gt; 1

```
tcgcgcgagt cgtctgnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnccgc 60
atcgtcctcc c 71
```

&lt;210&gt; 2

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;400&gt; 2

```
taatacgact cactataggg aggacgatgc gg 32
```

&lt;210&gt; 3

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid



WO 01/09390

PCT/US00/02167

<400> 3

tcgcgcgagt cgtctg

16

<210> 4

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 4

gggaggacga ugcggauc aaaacucacg uuauucccuc aucuauuagc uccccagac 60  
gacucgccc a 71

<210> 5

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 5

gggaggacga ugcggauc uccgaaaaag acucuuccug cauccucuca cccccagac 60  
gacucgccc a 71

<210> 6

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base



<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 9

gggaggacga ugcggcaaac gaucacuuac cuuuccugca ucugcuagcc uccccagac 60  
gacucgcccg a 71

<210> 10

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 10

gggaggacga ugcggacgcc agccauugac ccucgcuucc acuaauccau cccccagac 60  
gacucgcccg a 71

<210> 11

<211> 70

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<400> 11

gggaggacga ugcggccaac cucauuuuga cacuucgccg caccuaauug cccccagacg 60  
acucgcccga 70

<210> 12

<211> 15

<212> RNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(15)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 12

gacnyuuccn gcayc

15

&lt;210&gt; 13

&lt;211&gt; 71

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(71)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 13

gggaggacga ugcggaaccc auaacgcgaa ccgaccaaca ugccucccg ugcuccagac 60  
 gacucgccc a 71

&lt;210&gt; 14

&lt;211&gt; 70

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(70)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 14

gggaggacga ugcggugccc auagaagcgu gccgcuaaug cuaacgccc cccccagacg 60  
 acucgcccga 70

&lt;210&gt; 15

&lt;211&gt; 71

<212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>  
 <221> modified\_base  
 <222> (1)..(71)  
 <223> All pyrimidines are 2'F.

<400> 15  
 gggaggacga ugcggugccc acuaugcgug ccgaaaaaca uuucccccuc uaccccagac 60  
 gacucgccc a 71

<210> 16  
 <211> 71  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>  
 <221> modified\_base  
 <222> (1)..(71)  
 <223> All pyrimidines are 2'F.

<400> 16  
 gggaggacga ugcggaacac uuucccaugc gucgccauac cggauauauu gcucccagac 60  
 gacucgccc a 71

<210> 17  
 <211> 71  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>  
 <221> modified\_base  
 <222> (1)..(71)  
 <223> All pyrimidines are 2'F.

<400> 17  
 gggaggacga ugcggacugg accaaaccgu cgccgauacc cggauacuuu gcucccagac 60  
 gacucgccc a 71

<210> 18  
<211> 71  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Nucleic Acid

<220>  
<221> modified\_base  
<222> (1)..(71)  
<223> All pyrimidines are 2'F.

<400> 18  
gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccugcagac 60  
gacucgccc a 71

<210> 19  
<211> 71  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Nucleic Acid

<220>  
<221> modified\_base  
<222> (1)..(71)  
<223> All pyrimidines are 2'F.

<400> 19  
gggaggacga ugcgguaaag ucucgguuga augcccaucc cagauccecc ugacccagac 60  
gacucgccc a 71

<210> 20  
<211> 71  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Nucleic Acid

<220>  
<221> modified\_base  
<222> (1)..(71)  
<223> All pyrimidines are 2'F.

WO 01/09390

PCT/US00/02167

<400> 20

gggaggacga ugcggauggc aagucgaacc aucccccacg cuucuccugu ucccccagac 60  
gacucgccc a 71

<210> 21

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 21

gggaggacga ugcgggaagu uuucucugcc uggguuucga uggcgccuc cccccagac 60  
gacucgccc a 71

<210> 22

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 22

gggaggacga ugcggucgag cggucgaccg ucaacaagaa uaaagcgugu ccugcagac 60  
gacucgccc a 71

<210> 23

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base





<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 26

gggaggacga ugcggacgag cgucucauga ucacacuauu ucgucucagu gugcacagac 60  
gacucgcccg a 71

<210> 27

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 27

gggaggacga ugcggucgac cucgaaugac ucuccaccua ucuaacaucc cccccagac 60  
gacucgcccg a 71

<210> 28

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 28

gggaggacga ugcggucgac cucgaaugac ucuccaccua ucuaacagcc uccccagac 60  
gacucgcccg a 71

<210> 29

<211> 71

<212> RNA

<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(71)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 29

```

gggaggacga ugcggagaac ucauccuaac cgcucuaaca aaucuugucc gaccgcagac 60
gacucgcccg a                                     71

```

&lt;210&gt; 30

&lt;211&gt; 71

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(71)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 30

```

gggaggacga ugcggauaau ucgacaccaa ccaggucccg gaaaucaucc cucugcagac 60
gacucgcccg a                                     71

```

&lt;210&gt; 31

&lt;211&gt; 71

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(71)

&lt;223&gt; All pyrimidines are 2'F.

&lt;400&gt; 31

```

gggaggacga ugcggaaacc aaccguugac caccuuuucg uuuccggaaa guccccagac 60
gacucgcccg a                                     71

```

&lt;210&gt; 32



WO 01/09390

PCT/US00/02167

gacucgccccg a

71

<210> 35

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 35

gggaggacga ugcggaccaa cuaaacuguu cgaaagcuag aacacgucca gacgccagac 60  
 gacucgccccg a 71

<210> 36

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 36

gggaggacga ugcggaccaa cuaaacuguu cgaaagcugg aacacguucu gacgccagac 60  
 gacucgccccg a 71

<210> 37

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 37  
 gggaggacga ugcggaacaa cuaaacuguu cgaaagcugg aaucguccu gacgccagac 60  
 gacucgccc a 71

<210> 38  
 <211> 71  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>  
 <221> modified\_base  
 <222> (1)..(71)  
 <223> All pyrimidines are 2'F.

<400> 38  
 gggaggacga ugcggaaguu uagugcucca guccgacac uccucuacuc agccccagac 60  
 gacucgccc a 71

<210> 39  
 <211> 71  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>  
 <221> modified\_base  
 <222> (1)..(71)  
 <223> All pyrimidines are 2'F.

<400> 39  
 gggaggacga ugcggaacca gagccucucu caguucuaca gaacuuaccc acuggcagac 60  
 gacucgccc a 71

<210> 40  
 <211> 71  
 <212> RNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 40

gggaggacga ugcggaccua acucaaucag gaaccaaaacc uagcacucuc auggccagac 60  
gacucgcccg a 71

<210> 41

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 41

gggaggacga ugcgggagau caacauuccu cuaguuuggu uccaaccuac acccccagac 60  
gacucgcccg a 71

<210> 42

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 42

gggaggacga ugcggaucuc gauccuucag cacuucuuu cauuccuuuc ugccccagac 60  
gacucgcccg a 71

<210> 43

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 43

gggaggacga ugcggacgau ccuuuccuua acauuucauc auuucucuug ugccccagac 60  
gacucgcccg a 71

<210> 44

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<400> 44

gggaggacga ugcggugacg acaacucgac ugcauauuc acaacuccug ugccccagac 60  
gacucgcccg a 71

<210> 45

<211> 72

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(72)

<223> All pyrimidines are 2'F.

<400> 45

gggaggacga ugcggacuag accgcgaguc cauucaacu gcccacaaac cuccccaga 60  
cgacucgccc ga 72

<210> 46

<211> 70

<212> RNA

**WO 01/09390**
**PCT/US00/02167**

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<400> 46

gggaggacga ugcgggcgca ucgagcaaca uccgauucgg auuccuccac uccccagac 60  
 gacugcccga 70

<210> 47

<211> 50

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(50)

<223> All pyrimidines are 2'F; linkage at positions 50  
 and 51 is 3'-3'.

<400> 47

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu 50

<210> 48

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimdines are 2'F; linkage at positions 55  
 and 56 is 3'-3'.

<400> 48

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55





22 are 2'OMe; a's at positions 16-17, 19-20 and 24  
are 2'OMe; linkage at positions 55 and 56 is  
3'-3'.

<400> 51  
gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 52  
<211> 55  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Nucleic Acid

<220>  
<221> modified\_base  
<222> (1)..(55)  
<223> All pyrimidines are 2'F; g's at positions 38, 41  
and 44 are 2'OMe; linkage at positions 55 and 56  
is 3'-3'.

<400> 52  
gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 53  
<211> 55  
<212> RNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Nucleic Acid

<220>  
<221> modified\_base  
<222> (1)..(55)  
<223> All pyrimidines are 2'F; g's at positions 39-40,  
43 and 48 are 2'OMe; a's at positions 36-37 and 41  
are 2'OMe; linkage at positions 55 and 56 is  
3'-3'.

<400> 53  
gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 54  
<211> 55  
<212> RNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3,  
5-6, 9, 12, 14-15, 22, 28, 31, 34, 39-40, 43, 48  
and 55 are 2'OMe.

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(55)

<223> A's at positions 7, 10, 16-17, 19-20, 24, 36-37,  
and 41 are 2'OMe; linkage at positions 55 and 56  
is 3'-3'.

&lt;400&gt; 54

gggaggacga ugcggaacaa ugcacucguc gccgaaugg auguuugcu cccug 55

&lt;210&gt; 55

&lt;211&gt; 55

&lt;212&gt; RNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Nucleic Acid

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3,  
5-6, 9, 12, 14-15, 22, 39-40, 43, 48 and 55 are  
2'OMe; a's at positions 4,7, 10, 16-17,19-20,  
24-36-37, 40 are 2'OMe.

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (1)..(55)

&lt;223&gt; Linkage at positions 55 and 56 is 3'-3'.

&lt;400&gt; 55

gggaggacga ugcggaacaa ugcacucguc gccgaaugg auguuugcu cccug 55

&lt;210&gt; 56

&lt;211&gt; 55

&lt;212&gt; RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5-6, 15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 24 36-37 and 40 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 56

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 57

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5, 15, 22, 39-40, 43, 48, and 55 are 2'OMe; a's at positions 4, 7, 16-17, 19-20, 24, 36-37 and 40 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 57

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 58

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5,

9, 15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 24, 36-37 and 41 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 58

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu ccug 55

<210> 59

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5, 15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 10, 16-17, 19-20, 24, 36-37, and 41 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 59

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu ccug 55

<210> 60

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5, 12, 14-15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 24, 36-37 and 41 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 60

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu ccug 55

<210> 61

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 6, 15, 22, 28, 39-40, 43, 48, and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 24, 36-37 and 40 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 61

gggaggacga ugcggaacaa ugcacucguc gccgaaugg auguuuugcu cccug 55

<210> 62

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5, 15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 27, 36-37 and 40 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 62

gggaggacga ugcggaacaa ugcacucguc gccgaaugg auguuuugcu cccug 55

<210> 63

<211> 55

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(55)

<223> All pyrimidines are 2'F; g's at positions 1-3, 5,

15, 22, 39-40, 43, 48 and 55 are 2'OMe; a's at positions 4, 16-17, 19-20, 24, 36-37, and 40 are 2'OMe; linkage at positions 55 and 56 is 3'-3'.

<400> 63

gggaggacga ugcggaacaa ugcacucguc gccguaaugg auguuuugcu cccug 55

<210> 64

<211> 39

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(39)

<223> All pyrimidines are 2'F; g's at positions 2-3, 5-6, 23-24, 27, 32, and 39 are 2'OMe; a's at positions 4, 7, 20-21, and 25 are 2'OMe; N at position 10 is (CH<sub>2</sub>CH<sub>2</sub>O).

<220>

<221> modified\_base

<222> (1)..(39)

<223> Linkage at positions 39 and 40 is 3'-3'.

<400> 64

gggaggacgn cgucgccgua auggauguuu ugcucccug 39

<210> 65

<211> 34

<212> RNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Nucleic Acid

<220>

<221> modified\_base

<222> (1)..(34)

<223> All pyrimidines are 2'F; g's at positions 2-3, 5-6, 23-24, 27 and 32 are 2'OMe; a's at positions 4, 7, 20-21, and 25 are 2'OMe; N at position 10 is (CH<sub>2</sub>CH<sub>2</sub>O); linkage at positions 34 and 35 is 3'-3'.

